Skip to main content

Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2023 Results and Participation in Upcoming Investor Conference

SANTA CLARA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the third quarter 2023 after market close on Monday, November 6, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

On Wednesday, November 15, 2023, at 8:45 a.m. Eastern Time, Shockwave Medical management is scheduled to present at the 5th Annual Wolfe Research Healthcare Conference, which is taking place from Tuesday, November 14 - Wednesday, November 15, 2023, in New York, NY.

Interested parties may access live and archived webcasts of these events on the "Investors" section of the company’s website at Investors interested in dialing in to the third quarter 2023 Shockwave Medical earnings conference call on Monday November 6, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time may do so by dialing 877-704-4453 for domestic callers or 201-389-0920 for international callers, using conference ID: 13737257.

About Shockwave Medical, Inc.

Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at and

Media Contact:
Scott Shadiow

Investor Contact:
Debbie Kaster

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.